Ventyx Q2 2025 net loss $27M; positive Phase 2a data for VTX3232 in Parkinson's

Ventyx Biosciences, Inc.

2025-Q2 EPS reported -$0.76

Net loss $27M vs $32M in Q2 2024; cash $209M expected to fund operations into H2 2026.
Phase 2a of VTX3232 in early Parkinson's met safety goals, showed biomarker reductions and improved symptoms.
Phase 2 of VTX2735 in recurrent pericarditis on track for topline data in Q4 2025.
Phase 2 of VTX3232 in obesity/cardiometabolic fully enrolled; data expected early Q4 2025.
R&D expenses $22.3M, G&A $7.1M; both down YoY.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.